<DOC>
	<DOCNO>NCT01938261</DOCNO>
	<brief_summary>Present randomize , control , double-blind trial investigates efficacy safety early ( &lt; 24 h ) intravenous paracetamol therapy early closure ductus pain medication small premature infant . This phase 2 drug study focus efficacy safety short-term use . The pharmacokinetics pharmacodynamics paracetamol , well long-term effect , study . This study recruit preterm infant bear less 32 week gestational age treat neonatal intensive care unit Oulu University Hospital . The informed consent ask parent . The first drug dose give 24 hour age . Masked study drug paracetamol infusion solution 10 mg/mL ( PERFALGAN Â® ) placebo , 0.45 % saline solution . The load dose 20 mg/kg , maintenance dose 7.5 mg/kg every 6 hour 4 day . The exact date closure ductus study repeated echocardiographic examination . The symptom pain screen locally use pain scale preterm infant ( NIAPAS ) . Patients monitor sign possible side effect . After discharge hospital , patient examine follow-up clinic first year every 3 month 2 year age .</brief_summary>
	<brief_title>The Preterm Infants ' Paracetamol Study</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Ductus Arteriosus , Patent</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>preterm infant bear &lt; 32 week gestational age congenital malformation lethal disease chromosomal abnormality persistent pulmonary hypertension newborn</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Hours</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>